Items where Funder is Amgen Limited ***USE 819922***.

1T01-A321

Seligmann, JF, Domingo, E, Fisher, D et al. (17 more authors) (2022) The clinical relevance of tumor RAS/TP53 dual mutation in early and metastatic colorectal cancer (CRC). In: 2022 ASCO Annual Meeting, 03-07 Jun 2022, Chicago, Il, USA and Online.

Williams, C. orcid.org/0000-0002-1574-653X, Seligmann, J.F. orcid.org/0000-0003-4379-6005, Guetter, C. et al. (13 more authors) (2021) Artificial intelligence-assisted immunohistochemical (IHC) evaluation of tumor amphiregulin (AREG) and epiregulin (EREG) expression as a combined predictive biomarker for panitumumab (Pan) therapy benefit in RAS wild-type (wt) metastatic colorectal cancer (mCRC): Analysis within the phase III PICCOLO trial. In: Journal of Clinical Oncology. 2021 Gastrointestinal Cancers Symposium, 15-17 Jan 2021, Online. American Society of Clinical Oncology , p. 111.

2012-005111-12

Seligmann, JF, Domingo, E, Fisher, D et al. (17 more authors) (2022) The clinical relevance of tumor RAS/TP53 dual mutation in early and metastatic colorectal cancer (CRC). In: 2022 ASCO Annual Meeting, 03-07 Jun 2022, Chicago, Il, USA and Online.

Seligmann, JF, Domingo, E, Fisher, D et al. (17 more authors) (2022) The clinical relevance of tumor RAS/TP53 dual mutation in early and metastatic colorectal cancer (CRC). In: 2022 ASCO Annual Meeting, 03-07 Jun 2022, Chicago, Il, USA and Online.

4616

Seligmann, JF, Domingo, E, Fisher, D et al. (17 more authors) (2022) The clinical relevance of tumor RAS/TP53 dual mutation in early and metastatic colorectal cancer (CRC). In: 2022 ASCO Annual Meeting, 03-07 Jun 2022, Chicago, Il, USA and Online.

Williams, C. orcid.org/0000-0002-1574-653X, Seligmann, J.F. orcid.org/0000-0003-4379-6005, Guetter, C. et al. (13 more authors) (2021) Artificial intelligence-assisted immunohistochemical (IHC) evaluation of tumor amphiregulin (AREG) and epiregulin (EREG) expression as a combined predictive biomarker for panitumumab (Pan) therapy benefit in RAS wild-type (wt) metastatic colorectal cancer (mCRC): Analysis within the phase III PICCOLO trial. In: Journal of Clinical Oncology. 2021 Gastrointestinal Cancers Symposium, 15-17 Jan 2021, Online. American Society of Clinical Oncology , p. 111.

C6003/A15546

Seligmann, JF, Domingo, E, Fisher, D et al. (17 more authors) (2022) The clinical relevance of tumor RAS/TP53 dual mutation in early and metastatic colorectal cancer (CRC). In: 2022 ASCO Annual Meeting, 03-07 Jun 2022, Chicago, Il, USA and Online.

Williams, C. orcid.org/0000-0002-1574-653X, Seligmann, J.F. orcid.org/0000-0003-4379-6005, Guetter, C. et al. (13 more authors) (2021) Artificial intelligence-assisted immunohistochemical (IHC) evaluation of tumor amphiregulin (AREG) and epiregulin (EREG) expression as a combined predictive biomarker for panitumumab (Pan) therapy benefit in RAS wild-type (wt) metastatic colorectal cancer (mCRC): Analysis within the phase III PICCOLO trial. In: Journal of Clinical Oncology. 2021 Gastrointestinal Cancers Symposium, 15-17 Jan 2021, Online. American Society of Clinical Oncology , p. 111.

C6003/A6407

Williams, C. orcid.org/0000-0002-1574-653X, Seligmann, J.F. orcid.org/0000-0003-4379-6005, Guetter, C. et al. (13 more authors) (2021) Artificial intelligence-assisted immunohistochemical (IHC) evaluation of tumor amphiregulin (AREG) and epiregulin (EREG) expression as a combined predictive biomarker for panitumumab (Pan) therapy benefit in RAS wild-type (wt) metastatic colorectal cancer (mCRC): Analysis within the phase III PICCOLO trial. In: Journal of Clinical Oncology. 2021 Gastrointestinal Cancers Symposium, 15-17 Jan 2021, Online. American Society of Clinical Oncology , p. 111.

Williams, C. orcid.org/0000-0002-1574-653X, Seligmann, J.F. orcid.org/0000-0003-4379-6005, Guetter, C. et al. (13 more authors) (2021) Artificial intelligence-assisted immunohistochemical (IHC) evaluation of tumor amphiregulin (AREG) and epiregulin (EREG) expression as a combined predictive biomarker for panitumumab (Pan) therapy benefit in RAS wild-type (wt) metastatic colorectal cancer (mCRC): Analysis within the phase III PICCOLO trial. In: Journal of Clinical Oncology. 2021 Gastrointestinal Cancers Symposium, 15-17 Jan 2021, Online. American Society of Clinical Oncology , p. 111.

C6003/A7367

Seligmann, JF, Domingo, E, Fisher, D et al. (17 more authors) (2022) The clinical relevance of tumor RAS/TP53 dual mutation in early and metastatic colorectal cancer (CRC). In: 2022 ASCO Annual Meeting, 03-07 Jun 2022, Chicago, Il, USA and Online.

Williams, C. orcid.org/0000-0002-1574-653X, Seligmann, J.F. orcid.org/0000-0003-4379-6005, Guetter, C. et al. (13 more authors) (2021) Artificial intelligence-assisted immunohistochemical (IHC) evaluation of tumor amphiregulin (AREG) and epiregulin (EREG) expression as a combined predictive biomarker for panitumumab (Pan) therapy benefit in RAS wild-type (wt) metastatic colorectal cancer (mCRC): Analysis within the phase III PICCOLO trial. In: Journal of Clinical Oncology. 2021 Gastrointestinal Cancers Symposium, 15-17 Jan 2021, Online. American Society of Clinical Oncology , p. 111.

C7852/A19772

Seligmann, JF, Domingo, E, Fisher, D et al. (17 more authors) (2022) The clinical relevance of tumor RAS/TP53 dual mutation in early and metastatic colorectal cancer (CRC). In: 2022 ASCO Annual Meeting, 03-07 Jun 2022, Chicago, Il, USA and Online.

Williams, C. orcid.org/0000-0002-1574-653X, Seligmann, J.F. orcid.org/0000-0003-4379-6005, Guetter, C. et al. (13 more authors) (2021) Artificial intelligence-assisted immunohistochemical (IHC) evaluation of tumor amphiregulin (AREG) and epiregulin (EREG) expression as a combined predictive biomarker for panitumumab (Pan) therapy benefit in RAS wild-type (wt) metastatic colorectal cancer (mCRC): Analysis within the phase III PICCOLO trial. In: Journal of Clinical Oncology. 2021 Gastrointestinal Cancers Symposium, 15-17 Jan 2021, Online. American Society of Clinical Oncology , p. 111.

Fund No IT01

Seligmann, JF, Domingo, E, Fisher, D et al. (17 more authors) (2022) The clinical relevance of tumor RAS/TP53 dual mutation in early and metastatic colorectal cancer (CRC). In: 2022 ASCO Annual Meeting, 03-07 Jun 2022, Chicago, Il, USA and Online.

NOT GIVEN

Seligmann, JF, Domingo, E, Fisher, D et al. (17 more authors) (2022) The clinical relevance of tumor RAS/TP53 dual mutation in early and metastatic colorectal cancer (CRC). In: 2022 ASCO Annual Meeting, 03-07 Jun 2022, Chicago, Il, USA and Online.

Williams, C. orcid.org/0000-0002-1574-653X, Seligmann, J.F. orcid.org/0000-0003-4379-6005, Guetter, C. et al. (13 more authors) (2021) Artificial intelligence-assisted immunohistochemical (IHC) evaluation of tumor amphiregulin (AREG) and epiregulin (EREG) expression as a combined predictive biomarker for panitumumab (Pan) therapy benefit in RAS wild-type (wt) metastatic colorectal cancer (mCRC): Analysis within the phase III PICCOLO trial. In: Journal of Clinical Oncology. 2021 Gastrointestinal Cancers Symposium, 15-17 Jan 2021, Online. American Society of Clinical Oncology , p. 111.

RCS REF 08-0843 SUBCONTR

Seligmann, JF, Domingo, E, Fisher, D et al. (17 more authors) (2022) The clinical relevance of tumor RAS/TP53 dual mutation in early and metastatic colorectal cancer (CRC). In: 2022 ASCO Annual Meeting, 03-07 Jun 2022, Chicago, Il, USA and Online.

TS/S012702/1 104687

Williams, C. orcid.org/0000-0002-1574-653X, Seligmann, J.F. orcid.org/0000-0003-4379-6005, Guetter, C. et al. (13 more authors) (2021) Artificial intelligence-assisted immunohistochemical (IHC) evaluation of tumor amphiregulin (AREG) and epiregulin (EREG) expression as a combined predictive biomarker for panitumumab (Pan) therapy benefit in RAS wild-type (wt) metastatic colorectal cancer (mCRC): Analysis within the phase III PICCOLO trial. In: Journal of Clinical Oncology. 2021 Gastrointestinal Cancers Symposium, 15-17 Jan 2021, Online. American Society of Clinical Oncology , p. 111.